Trial · NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871, Phase 1, Phase 2, Recruiting, Radiopharm Theranostics, Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors. Trials, record NCT07189871. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07189871
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- NCT number
- NCT07189871
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 61 participants, estimated
- Lead sponsor
- Radiopharm Theranostics, Ltd
- Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
- Interventions
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- First posted
- 2025-09-24
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of 177LuBetaBart | 6 weeks | TEAEs as defined by CTCAE v5.0 |
| Primary | To assess the preliminary anti-tumor activity of 177Lu-BetaBart at the RP2D | Up to 30 weeks | ORR per RECIST v1.1 and iRECIST |
| Primary | To assess preliminary anti-tumor activity, as defined by biochemical response, in CRPC participants at the RP2D | Up to 30 weeks | Proportion of participants who achieve a best response of PSA50 |
| Secondary | To assess the preliminary anti-tumor activity of 177Lu-BetaBart | Up to 30 weeks | ORR per RECIST v1.1 and iRECIST |
| Secondary | To assess preliminary anti-tumor activity, as defined by biochemical response, in CRPC participants | Up to 30 weeks | Proportion of participants who achieve a best response of PSA50 |
| Secondary | Assess biodistrubution, PK, and radiation dosimetry of 177Lu-BetaBart | 6 weeks | Absorbed Radiation doses in critical organs |
| Secondary | Effect of Co-injection of unlabeled BetaBart on biodistribution of radiolabeled 177Lu-BetaBart | 6 weeks | Absorbed Radiation doses in critical organs |
| Secondary | To assess preliminary anti-tumor activity, as defined by biochemical response, in CRPC participants who were previously treated with at least one ARSI | Up to 30 weeks | bPFS as assessed by PCWG3 |
| Secondary | Safety and Tolerability of 177LuBetaBart at the RP2D | 6 weeks | TEAEs as defined by CTCAE v5.0 |
| Secondary | Assess biodistribution, PK, and radiation dosimetry of 177Lu-BetaBart at the RP2D | 6 weeks | Absorbed Radiation doses in critical organs |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07189871
GET https://conductscience.org/api/trials/v1/NCT07189871/registered